Table 3.
EUCAST MIC cut-off values defining susceptibility to new β-lactam/β-lactamase inhibitor combinations and cefiderocol for Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia
Ceftolozane–tazobactam | Ceftazidime–avibactam | Imipenem–relebactam | Meropenem–vaborbactam | Cefiderocol | |
---|---|---|---|---|---|
Enterobacterales | ≤ 2 mg/L | ≤ 8 mg/L | ≤ 2 mg/L | ≤ 8 mg/L | ≤ 2 mg/L |
Pseudomonas aeruginosa | ≤ 4 mg/L | ≤ 8 mg/L | ≤ 2 mg/L | ≤ 8 mg/L | ≤ 2 mg/L |
Acinetobacter baumannii | IR | NA | ≤ 2 mg/L | ≤ 2 mg/L a | NA |
Stenotrophomonas maltophilia | IR | NA | IR | IR | NA |
Source: www.eucast.org/clinical_breakpoints
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimal inhibitory concentration; IR: intrinsic resistance; NA: non-appropriate (species with intrinsically weak susceptibility to the considered drug or insufficient data to define a MIC cut-off value)
aMIC cut-off for meropenem